Oligodendroglioma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Oligodendroglioma – Pipeline Review, H2 2017’, provides an overview of the Oligodendroglioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma

The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects

The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Oligodendroglioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AngioChem Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cavion LLC

Celldex Therapeutics Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Immatics Biotechnologies GmbH

Ipsen SA

Leadiant Biosciences Inc

Millennium Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Pfizer Inc

Tocagen Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Oligodendroglioma - Overview 6

Oligodendroglioma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Oligodendroglioma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Oligodendroglioma - Companies Involved in Therapeutics Development 21

AngioChem Inc 21

Boehringer Ingelheim GmbH 21

Bristol-Myers Squibb Co 21

Cavion LLC 22

Celldex Therapeutics Inc 22

Eli Lilly and Co 23

F. Hoffmann-La Roche Ltd 23

Immatics Biotechnologies GmbH 24

Ipsen SA 24

Leadiant Biosciences Inc 24

Millennium Pharmaceuticals Inc 25

Northwest Biotherapeutics Inc 25

Novartis AG 26

Pfizer Inc 26

Tocagen Inc 27

Oligodendroglioma - Drug Profiles 28

abemaciclib - Drug Profile 28

afatinib dimaleate - Drug Profile 36

alisertib - Drug Profile 50

bevacizumab - Drug Profile 56

CDX-1401 - Drug Profile 68

Cellular Immunotherapy for Gliomas - Drug Profile 71

Cellular Immunotherapy for Oncology - Drug Profile 72

dasatinib - Drug Profile 73

DCVax-L - Drug Profile 77

flucytosine + TBio-01 - Drug Profile 85

flucytosine ER + vocimagene amiretrorepvec - Drug Profile 86

IMA-950 - Drug Profile 96

irinotecan hydrochloride - Drug Profile 98

irinotecan hydrochloride + TBio-02 - Drug Profile 110

mibefradil dihydrochloride - Drug Profile 112

nilotinib - Drug Profile 115

p28 - Drug Profile 122

paclitaxel trevatide - Drug Profile 124

palbociclib - Drug Profile 129

procarbazine hydrochloride - Drug Profile 142

TBX.OncV NSC - Drug Profile 143

Oligodendroglioma - Dormant Projects 144

Oligodendroglioma - Discontinued Products 145

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147

List of Tables

List of Tables

Number of Products under Development for Oligodendroglioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Oligodendroglioma – Pipeline by AngioChem Inc, H2 2017

Oligodendroglioma – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Oligodendroglioma – Pipeline by Bristol-Myers Squibb Co, H2 2017

Oligodendroglioma – Pipeline by Cavion LLC, H2 2017

Oligodendroglioma – Pipeline by Celldex Therapeutics Inc, H2 2017

Oligodendroglioma – Pipeline by Eli Lilly and Co, H2 2017

Oligodendroglioma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Oligodendroglioma – Pipeline by Immatics Biotechnologies GmbH, H2 2017

Oligodendroglioma – Pipeline by Ipsen SA, H2 2017

Oligodendroglioma – Pipeline by Leadiant Biosciences Inc, H2 2017

Oligodendroglioma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Oligodendroglioma – Pipeline by Northwest Biotherapeutics Inc, H2 2017

Oligodendroglioma – Pipeline by Novartis AG, H2 2017

Oligodendroglioma – Pipeline by Pfizer Inc, H2 2017

Oligodendroglioma – Pipeline by Tocagen Inc, H2 2017

Oligodendroglioma – Dormant Projects, H2 2017

Oligodendroglioma – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Oligodendroglioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports